Published • loading... • Updated
Anvisa Records Two Injection Pens of Semaglutide for Treatment of Type 2 Diabetes in Adults
Summary by Portal Mix Vale
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The National Agency of Health Surveillance (Anvisa) announced on Monday, August 17, 2026, the approval of the registration of two new injectable drugs based on synthetic semaglutide. Devices, which function as GLP-1 receptor agonists, are developed for the control of type 2 diabetes mellitus in adult patients. The measure represents [...]
·Brazil
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
